FDA OK'd its second obesity device this year on July 28, with the PMA approval for ReShape Medical Inc.'s ReShape weight-loss system. On the same day, Aspire Bariatrics Inc. announced a PMA submission for its AspireAssist aspiration therapy weight-loss device, reflecting the increasingly active field of prospective device competitors in the obesity space.
ReShape's integrated dual intragastric balloon system, which was previously CE marked, is designed to occupy space in the stomach to trigger feelings of fullness, but its precise mechanism of action...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?